John B. Johnson
Rajiv Gandhi Centre for Biotechnology
25 Papers
90 Citations
John B. Johnson is an academic researcher from Rajiv Gandhi Centre for Biotechnology. The author has contributed to research in topics: Complement system & Virus. The author has an hindex of 13, co-authored 23 publications. Previous affiliations of John B. Johnson include Wake Forest University.
Chat about Author
Papers
Critical insights into antibiotic resistance transferability in probiotic Lactobacillus.
TL;DR: The aim of this review was to describe the pros and cons of drug resistance among these beneficial microorganisms with emphasis on the recommended selection criteria for specific probiotics, devoid of transferable drug resistance genes, suitable for human consumption.
92
A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in Mice
TL;DR: Flagellin-L1R and flagell in-B5R fusion proteins are effective in eliciting protective immunity against vaccinia virus that is dependent, in large part, on complement.
62
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.
TL;DR: The results indicate that even though antibodies exist that recognize both SV5 and MuV, they are mostly non-neutralizing and viral inactivation in vitro occurs through the alternative pathway of complement.
56
TLR-4 and -6 agonists reverse apoptosis and promote maturation of simian virus 5-infected human dendritic cells through NFkB-dependent pathways
TL;DR: The results suggest a model whereby SV5 replication induces apoptosis in immature DC but fails to provide strong maturation signals, while activation of NFkB-dependent pathways by exogenous ligands can lead to moDC maturation and override SV5-induced cell death.
41
Incorporation of Host Complement Regulatory Proteins into Newcastle Disease Virus Enhances Complement Evasion
TL;DR: Newcastle disease virus (NDV), an avian paramyxovirus, is inherently tumor selective and is currently being considered as a clinical oncolytic virus and vaccine vector.
40